nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—CYP3A4—Pilocarpine—glaucoma	0.0753	0.236	CbGbCtD
Everolimus—CYP3A4—Brinzolamide—glaucoma	0.0591	0.185	CbGbCtD
Everolimus—CYP3A4—Dorzolamide—glaucoma	0.0571	0.178	CbGbCtD
Everolimus—CYP3A4—Methazolamide—glaucoma	0.0508	0.159	CbGbCtD
Everolimus—CYP3A4—Acetazolamide—glaucoma	0.0407	0.127	CbGbCtD
Everolimus—CYP3A4—Clonidine—glaucoma	0.0368	0.115	CbGbCtD
Everolimus—MTOR—Signaling by PDGF—NCK2—glaucoma	0.00083	0.00414	CbGpPWpGaD
Everolimus—CYP3A4—Estrogen metabolism—CYP1B1—glaucoma	0.00076	0.00379	CbGpPWpGaD
Everolimus—MTOR—Type II diabetes mellitus—TNF—glaucoma	0.000743	0.00371	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—BAD—glaucoma	0.000729	0.00364	CbGpPWpGaD
Everolimus—MTOR—IL4-mediated signaling events—BCL2L1—glaucoma	0.000721	0.0036	CbGpPWpGaD
Everolimus—MTOR—Class I PI3K signaling events mediated by Akt—CDKN1B—glaucoma	0.000719	0.00359	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—NTRK1—glaucoma	0.000704	0.00352	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—MMP1—glaucoma	0.000697	0.00348	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—EDN1—glaucoma	0.000676	0.00337	CbGpPWpGaD
Everolimus—CYP3A4—Tamoxifen metabolism—CYP1B1—glaucoma	0.000672	0.00335	CbGpPWpGaD
Everolimus—FKBP1A—Disease—LRP12—glaucoma	0.000667	0.00333	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—NTRK1—glaucoma	0.00066	0.00329	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CDKN2B—glaucoma	0.000649	0.00324	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—BDNF—glaucoma	0.000645	0.00322	CbGpPWpGaD
Everolimus—FKBP1A—TGF-beta Receptor Signaling—TNF—glaucoma	0.000644	0.00321	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—RPTOR—glaucoma	0.000636	0.00318	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—BCL2L1—glaucoma	0.000619	0.00309	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—NTRK2—glaucoma	0.000609	0.00304	CbGpPWpGaD
Everolimus—CYP3A4—Estrogen metabolism—GSTM1—glaucoma	0.000608	0.00303	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IL1A—glaucoma	0.000562	0.00281	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—BAD—glaucoma	0.000561	0.0028	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—FAS—glaucoma	0.000552	0.00276	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—TXN—glaucoma	0.000541	0.0027	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—NGF—glaucoma	0.000536	0.00268	CbGpPWpGaD
Everolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—BAD—glaucoma	0.000533	0.00266	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—NGFR—glaucoma	0.000523	0.00261	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—BAD—glaucoma	0.000512	0.00256	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—PTGS2—glaucoma	0.00051	0.00255	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—CDKN1B—glaucoma	0.000508	0.00254	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—BAD—glaucoma	0.000503	0.00251	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—NTRK1—glaucoma	0.000497	0.00248	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—CDKN1B—glaucoma	0.000483	0.00241	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—BCL2L1—glaucoma	0.000473	0.00236	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	0.000472	0.00236	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—LRP12—glaucoma	0.000467	0.00233	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NTRK2—glaucoma	0.000457	0.00228	CbGpPWpGaD
Everolimus—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	0.000457	0.00228	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—BDNF—glaucoma	0.000455	0.00227	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—BAD—glaucoma	0.000453	0.00226	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—NOS3—glaucoma	0.000451	0.00225	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—CAV1—glaucoma	0.000449	0.00224	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—MMP9—glaucoma	0.000448	0.00223	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—BAD—glaucoma	0.000442	0.00221	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—BAD—glaucoma	0.000439	0.00219	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—CDKN1B—glaucoma	0.000438	0.00219	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—FN1—glaucoma	0.000434	0.00216	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—CDKN1B—glaucoma	0.000433	0.00216	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FGFR1OP—glaucoma	0.00043	0.00214	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HEYL—glaucoma	0.00043	0.00214	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—BAD—glaucoma	0.000428	0.00214	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—BAD—glaucoma	0.000428	0.00214	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—CAV1—glaucoma	0.000424	0.00211	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—CDKN1B—glaucoma	0.000422	0.00211	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CTSA—glaucoma	0.000418	0.00209	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—NGF—glaucoma	0.000404	0.00201	CbGpPWpGaD
Everolimus—MTOR—LKB1 signaling events—TP53—glaucoma	0.000383	0.00191	CbGpPWpGaD
Everolimus—MTOR—Disease—LRP12—glaucoma	0.000375	0.00187	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NTRK1—glaucoma	0.000373	0.00186	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—TXNIP—glaucoma	0.000366	0.00183	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—VEGFA—glaucoma	0.000364	0.00182	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—TBK1—glaucoma	0.000359	0.00179	CbGpPWpGaD
Everolimus—CYP3A4—Tryptophan metabolism—CYP1B1—glaucoma	0.000359	0.00179	CbGpPWpGaD
Everolimus—MTOR—Cardiac Hypertrophic Response—TNF—glaucoma	0.000357	0.00178	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—MMP1—glaucoma	0.000355	0.00177	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—NTRK2—glaucoma	0.000352	0.00176	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—CDKN1B—glaucoma	0.00035	0.00175	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	0.000347	0.00173	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TNF—glaucoma	0.000344	0.00172	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—NOS3—glaucoma	0.000339	0.00169	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—BAD—glaucoma	0.000338	0.00169	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—CDKN2A—glaucoma	0.000337	0.00168	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—BAD—glaucoma	0.000333	0.00166	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—MMP9—glaucoma	0.00033	0.00165	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	0.000329	0.00164	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—C1QB—glaucoma	0.000325	0.00162	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—BAD—glaucoma	0.000324	0.00162	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—OPN4—glaucoma	0.000324	0.00162	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—CAV1—glaucoma	0.000322	0.00161	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—BAD—glaucoma	0.00032	0.0016	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—NOS3—glaucoma	0.00032	0.0016	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—TP53—glaucoma	0.000319	0.00159	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—BAD—glaucoma	0.000319	0.00159	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—CDKN1B—glaucoma	0.000315	0.00157	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—CDKN1B—glaucoma	0.000308	0.00154	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—CDKN1B—glaucoma	0.000305	0.00152	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—BAD—glaucoma	0.000304	0.00152	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TP53—glaucoma	0.000304	0.00152	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NGF—glaucoma	0.000303	0.00151	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—BAD—glaucoma	0.000303	0.00151	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—NGFR—glaucoma	0.000302	0.00151	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—BAD—glaucoma	0.000301	0.0015	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HEYL—glaucoma	0.000301	0.0015	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—BAD—glaucoma	0.0003	0.0015	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—CDKN1B—glaucoma	0.000298	0.00149	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—CDKN1B—glaucoma	0.000298	0.00149	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—SOD1—glaucoma	0.000298	0.00149	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—BAD—glaucoma	0.000296	0.00148	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTGFR—glaucoma	0.000291	0.00145	CbGpPWpGaD
Everolimus—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	0.00029	0.00145	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—TXN—glaucoma	0.00029	0.00145	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—NTRK1—glaucoma	0.000287	0.00143	CbGpPWpGaD
Everolimus—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—glaucoma	0.000286	0.00143	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—BAD—glaucoma	0.000282	0.00141	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—BAD—glaucoma	0.000282	0.00141	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—BAD—glaucoma	0.000282	0.00141	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—CDKN2B—glaucoma	0.000282	0.00141	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—BAD—glaucoma	0.00028	0.0014	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—BAD—glaucoma	0.000277	0.00138	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—BAD—glaucoma	0.000276	0.00138	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—TP53—glaucoma	0.000275	0.00137	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	0.000273	0.00136	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—IL1A—glaucoma	0.000269	0.00134	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HDAC9—glaucoma	0.000268	0.00134	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—LRP12—glaucoma	0.000263	0.00131	CbGpPWpGaD
Everolimus—MTOR—AMPK Signaling—TP53—glaucoma	0.000262	0.00131	CbGpPWpGaD
Everolimus—Pain—Brinzolamide—glaucoma	0.000261	0.000544	CcSEcCtD
Everolimus—MTOR—B Cell Activation—BAD—glaucoma	0.000261	0.0013	CbGpPWpGaD
Everolimus—Somnolence—Pilocarpine—glaucoma	0.000261	0.000544	CcSEcCtD
Everolimus—Angiopathy—Betaxolol—glaucoma	0.000261	0.000543	CcSEcCtD
Everolimus—Pruritus—Bimatoprost—glaucoma	0.00026	0.000542	CcSEcCtD
Everolimus—Immune system disorder—Betaxolol—glaucoma	0.00026	0.000541	CcSEcCtD
Everolimus—Diarrhoea—Apraclonidine—glaucoma	0.000259	0.00054	CcSEcCtD
Everolimus—Malaise—Clonidine—glaucoma	0.000259	0.00054	CcSEcCtD
Everolimus—Mediastinal disorder—Betaxolol—glaucoma	0.000259	0.00054	CcSEcCtD
Everolimus—Dyspepsia—Pilocarpine—glaucoma	0.000258	0.000538	CcSEcCtD
Everolimus—Chills—Betaxolol—glaucoma	0.000258	0.000537	CcSEcCtD
Everolimus—Syncope—Clonidine—glaucoma	0.000258	0.000537	CcSEcCtD
Everolimus—Feeling abnormal—Dorzolamide—glaucoma	0.000256	0.000533	CcSEcCtD
Everolimus—Decreased appetite—Pilocarpine—glaucoma	0.000255	0.000532	CcSEcCtD
Everolimus—Feeling abnormal—Travoprost—glaucoma	0.000255	0.000531	CcSEcCtD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—glaucoma	0.000254	0.00127	CbGpPWpGaD
Everolimus—Conjunctivitis—Timolol—glaucoma	0.000254	0.00053	CcSEcCtD
Everolimus—Gastrointestinal pain—Dorzolamide—glaucoma	0.000254	0.000529	CcSEcCtD
Everolimus—Alopecia—Betaxolol—glaucoma	0.000254	0.000529	CcSEcCtD
Everolimus—Palpitations—Clonidine—glaucoma	0.000254	0.000529	CcSEcCtD
Everolimus—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000254	0.000528	CcSEcCtD
Everolimus—MTOR—Immune System—CTSA—glaucoma	0.000253	0.00127	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Travoprost—glaucoma	0.000253	0.000527	CcSEcCtD
Everolimus—Loss of consciousness—Clonidine—glaucoma	0.000253	0.000526	CcSEcCtD
Everolimus—Feeling abnormal—Brinzolamide—glaucoma	0.000252	0.000524	CcSEcCtD
Everolimus—Mental disorder—Betaxolol—glaucoma	0.000252	0.000524	CcSEcCtD
Everolimus—Pain—Pilocarpine—glaucoma	0.000251	0.000523	CcSEcCtD
Everolimus—Constipation—Pilocarpine—glaucoma	0.000251	0.000523	CcSEcCtD
Everolimus—Cough—Clonidine—glaucoma	0.000251	0.000522	CcSEcCtD
Everolimus—Dizziness—Apraclonidine—glaucoma	0.000251	0.000522	CcSEcCtD
Everolimus—Malnutrition—Betaxolol—glaucoma	0.00025	0.000521	CcSEcCtD
Everolimus—Erythema—Betaxolol—glaucoma	0.00025	0.000521	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—BAD—glaucoma	0.00025	0.00125	CbGpPWpGaD
Everolimus—Epistaxis—Timolol—glaucoma	0.000247	0.000514	CcSEcCtD
Everolimus—Abdominal pain—Dorzolamide—glaucoma	0.000246	0.000512	CcSEcCtD
Everolimus—Body temperature increased—Dorzolamide—glaucoma	0.000246	0.000512	CcSEcCtD
Everolimus—Sinusitis—Timolol—glaucoma	0.000245	0.000511	CcSEcCtD
Everolimus—Dysgeusia—Betaxolol—glaucoma	0.000245	0.00051	CcSEcCtD
Everolimus—Chest pain—Clonidine—glaucoma	0.000245	0.00051	CcSEcCtD
Everolimus—Arthralgia—Clonidine—glaucoma	0.000245	0.00051	CcSEcCtD
Everolimus—Abdominal pain—Travoprost—glaucoma	0.000245	0.00051	CcSEcCtD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—VEGFA—glaucoma	0.000244	0.00122	CbGpPWpGaD
Everolimus—Anxiety—Clonidine—glaucoma	0.000244	0.000508	CcSEcCtD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—NOS3—glaucoma	0.000243	0.00122	CbGpPWpGaD
Everolimus—Asthenia—Acetazolamide—glaucoma	0.000243	0.000507	CcSEcCtD
Everolimus—Dizziness—Bimatoprost—glaucoma	0.000243	0.000506	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000243	0.000506	CcSEcCtD
Everolimus—Feeling abnormal—Pilocarpine—glaucoma	0.000242	0.000504	CcSEcCtD
Everolimus—Discomfort—Clonidine—glaucoma	0.000242	0.000503	CcSEcCtD
Everolimus—MTOR—Disease—HEYL—glaucoma	0.000242	0.00121	CbGpPWpGaD
Everolimus—MTOR—Disease—FGFR1OP—glaucoma	0.000242	0.00121	CbGpPWpGaD
Everolimus—Vomiting—Apraclonidine—glaucoma	0.000241	0.000502	CcSEcCtD
Everolimus—Muscle spasms—Betaxolol—glaucoma	0.000241	0.000501	CcSEcCtD
Everolimus—Gastrointestinal pain—Pilocarpine—glaucoma	0.00024	0.0005	CcSEcCtD
Everolimus—Hypersensitivity—Brimonidine—glaucoma	0.00024	0.000499	CcSEcCtD
Everolimus—Dry mouth—Clonidine—glaucoma	0.000239	0.000498	CcSEcCtD
Everolimus—Dermatitis—Apraclonidine—glaucoma	0.000239	0.000497	CcSEcCtD
Everolimus—Headache—Apraclonidine—glaucoma	0.000237	0.000495	CcSEcCtD
Everolimus—Vision blurred—Betaxolol—glaucoma	0.000236	0.000491	CcSEcCtD
Everolimus—MTOR—Signaling by SCF-KIT—CDKN1B—glaucoma	0.000236	0.00118	CbGpPWpGaD
Everolimus—Rhinitis—Timolol—glaucoma	0.000235	0.00049	CcSEcCtD
Everolimus—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	0.000235	0.00117	CbGpPWpGaD
Everolimus—Oedema—Clonidine—glaucoma	0.000235	0.000489	CcSEcCtD
Everolimus—Tremor—Betaxolol—glaucoma	0.000234	0.000488	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	0.000234	0.00117	CbGpPWpGaD
Everolimus—Hallucination—Timolol—glaucoma	0.000234	0.000487	CcSEcCtD
Everolimus—Asthenia—Brimonidine—glaucoma	0.000233	0.000486	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—NGF—glaucoma	0.000233	0.00116	CbGpPWpGaD
Everolimus—Infection—Clonidine—glaucoma	0.000233	0.000485	CcSEcCtD
Everolimus—Abdominal pain—Pilocarpine—glaucoma	0.000232	0.000484	CcSEcCtD
Everolimus—Body temperature increased—Pilocarpine—glaucoma	0.000232	0.000484	CcSEcCtD
Everolimus—Ill-defined disorder—Betaxolol—glaucoma	0.000232	0.000484	CcSEcCtD
Everolimus—Diarrhoea—Acetazolamide—glaucoma	0.000232	0.000483	CcSEcCtD
Everolimus—Rash—Bimatoprost—glaucoma	0.000232	0.000483	CcSEcCtD
Everolimus—Dermatitis—Bimatoprost—glaucoma	0.000232	0.000482	CcSEcCtD
Everolimus—Oedema peripheral—Timolol—glaucoma	0.000231	0.000482	CcSEcCtD
Everolimus—Anaemia—Betaxolol—glaucoma	0.000231	0.000482	CcSEcCtD
Everolimus—MTOR—Signaling by VEGF—VEGFA—glaucoma	0.000231	0.00115	CbGpPWpGaD
Everolimus—Shock—Clonidine—glaucoma	0.000231	0.000481	CcSEcCtD
Everolimus—Connective tissue disorder—Timolol—glaucoma	0.000231	0.000481	CcSEcCtD
Everolimus—Pruritus—Brimonidine—glaucoma	0.00023	0.00048	CcSEcCtD
Everolimus—Headache—Bimatoprost—glaucoma	0.00023	0.00048	CcSEcCtD
Everolimus—Nervous system disorder—Clonidine—glaucoma	0.00023	0.000479	CcSEcCtD
Everolimus—Thrombocytopenia—Clonidine—glaucoma	0.00023	0.000478	CcSEcCtD
Everolimus—Hypersensitivity—Dorzolamide—glaucoma	0.000229	0.000477	CcSEcCtD
Everolimus—Tachycardia—Clonidine—glaucoma	0.000229	0.000477	CcSEcCtD
Everolimus—Hypersensitivity—Travoprost—glaucoma	0.000228	0.000475	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—RPTOR—glaucoma	0.000228	0.00114	CbGpPWpGaD
Everolimus—Skin disorder—Clonidine—glaucoma	0.000228	0.000474	CcSEcCtD
Everolimus—Hyperhidrosis—Clonidine—glaucoma	0.000227	0.000472	CcSEcCtD
Everolimus—Malaise—Betaxolol—glaucoma	0.000226	0.00047	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—CDKN1B—glaucoma	0.000226	0.00113	CbGpPWpGaD
Everolimus—Nausea—Apraclonidine—glaucoma	0.000225	0.000469	CcSEcCtD
Everolimus—Hypersensitivity—Brinzolamide—glaucoma	0.000225	0.000469	CcSEcCtD
Everolimus—Syncope—Betaxolol—glaucoma	0.000224	0.000467	CcSEcCtD
Everolimus—Dizziness—Acetazolamide—glaucoma	0.000224	0.000467	CcSEcCtD
Everolimus—Anorexia—Clonidine—glaucoma	0.000224	0.000466	CcSEcCtD
Everolimus—Asthenia—Dorzolamide—glaucoma	0.000223	0.000464	CcSEcCtD
Everolimus—Asthenia—Travoprost—glaucoma	0.000222	0.000462	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—CDKN1B—glaucoma	0.000222	0.00111	CbGpPWpGaD
Everolimus—Palpitations—Betaxolol—glaucoma	0.000221	0.000461	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—NCK2—glaucoma	0.000221	0.0011	CbGpPWpGaD
Everolimus—Pruritus—Dorzolamide—glaucoma	0.00022	0.000458	CcSEcCtD
Everolimus—Loss of consciousness—Betaxolol—glaucoma	0.00022	0.000458	CcSEcCtD
Everolimus—Eye disorder—Timolol—glaucoma	0.000219	0.000457	CcSEcCtD
Everolimus—Asthenia—Brinzolamide—glaucoma	0.000219	0.000457	CcSEcCtD
Everolimus—Hypotension—Clonidine—glaucoma	0.000219	0.000456	CcSEcCtD
Everolimus—Pruritus—Travoprost—glaucoma	0.000219	0.000456	CcSEcCtD
Everolimus—MTOR—Signaling by SCF-KIT—MMP9—glaucoma	0.000218	0.00109	CbGpPWpGaD
Everolimus—Cough—Betaxolol—glaucoma	0.000218	0.000455	CcSEcCtD
Everolimus—Nausea—Bimatoprost—glaucoma	0.000218	0.000455	CcSEcCtD
Everolimus—Cardiac disorder—Timolol—glaucoma	0.000218	0.000454	CcSEcCtD
Everolimus—Hypersensitivity—Pilocarpine—glaucoma	0.000216	0.000451	CcSEcCtD
Everolimus—Pruritus—Brinzolamide—glaucoma	0.000216	0.00045	CcSEcCtD
Everolimus—Vomiting—Acetazolamide—glaucoma	0.000216	0.000449	CcSEcCtD
Everolimus—Dizziness—Brimonidine—glaucoma	0.000215	0.000448	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Clonidine—glaucoma	0.000214	0.000445	CcSEcCtD
Everolimus—MTOR—Immune System—TXNIP—glaucoma	0.000213	0.00106	CbGpPWpGaD
Everolimus—Angiopathy—Timolol—glaucoma	0.000213	0.000444	CcSEcCtD
Everolimus—Arthralgia—Betaxolol—glaucoma	0.000213	0.000444	CcSEcCtD
Everolimus—Chest pain—Betaxolol—glaucoma	0.000213	0.000444	CcSEcCtD
Everolimus—Myalgia—Betaxolol—glaucoma	0.000213	0.000444	CcSEcCtD
Everolimus—Diarrhoea—Dorzolamide—glaucoma	0.000213	0.000443	CcSEcCtD
Everolimus—Headache—Acetazolamide—glaucoma	0.000212	0.000442	CcSEcCtD
Everolimus—Anxiety—Betaxolol—glaucoma	0.000212	0.000442	CcSEcCtD
Everolimus—Insomnia—Clonidine—glaucoma	0.000212	0.000442	CcSEcCtD
Everolimus—Immune system disorder—Timolol—glaucoma	0.000212	0.000442	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—CDKN1B—glaucoma	0.000212	0.00106	CbGpPWpGaD
Everolimus—Diarrhoea—Travoprost—glaucoma	0.000212	0.000441	CcSEcCtD
Everolimus—Mediastinal disorder—Timolol—glaucoma	0.000212	0.000441	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000212	0.000441	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR—CDKN1B—glaucoma	0.000211	0.00105	CbGpPWpGaD
Everolimus—Asthenia—Pilocarpine—glaucoma	0.000211	0.000439	CcSEcCtD
Everolimus—Paraesthesia—Clonidine—glaucoma	0.000211	0.000439	CcSEcCtD
Everolimus—Discomfort—Betaxolol—glaucoma	0.00021	0.000438	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—CDKN1B—glaucoma	0.00021	0.00105	CbGpPWpGaD
Everolimus—MTOR—Immune System—TBK1—glaucoma	0.000209	0.00104	CbGpPWpGaD
Everolimus—Dyspnoea—Clonidine—glaucoma	0.000209	0.000436	CcSEcCtD
Everolimus—Diarrhoea—Brinzolamide—glaucoma	0.000209	0.000435	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—CDKN1B—glaucoma	0.000209	0.00104	CbGpPWpGaD
Everolimus—Somnolence—Clonidine—glaucoma	0.000208	0.000434	CcSEcCtD
Everolimus—Dry mouth—Betaxolol—glaucoma	0.000208	0.000434	CcSEcCtD
Everolimus—Pruritus—Pilocarpine—glaucoma	0.000208	0.000433	CcSEcCtD
Everolimus—Alopecia—Timolol—glaucoma	0.000207	0.000432	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	0.000207	0.00103	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—CDKN1B—glaucoma	0.000206	0.00103	CbGpPWpGaD
Everolimus—Mental disorder—Timolol—glaucoma	0.000206	0.000428	CcSEcCtD
Everolimus—Dizziness—Dorzolamide—glaucoma	0.000206	0.000428	CcSEcCtD
Everolimus—Rash—Brimonidine—glaucoma	0.000205	0.000427	CcSEcCtD
Everolimus—Dermatitis—Brimonidine—glaucoma	0.000205	0.000427	CcSEcCtD
Everolimus—Dizziness—Travoprost—glaucoma	0.000205	0.000426	CcSEcCtD
Everolimus—Malnutrition—Timolol—glaucoma	0.000204	0.000426	CcSEcCtD
Everolimus—Erythema—Timolol—glaucoma	0.000204	0.000426	CcSEcCtD
Everolimus—Oedema—Betaxolol—glaucoma	0.000204	0.000425	CcSEcCtD
Everolimus—Headache—Brimonidine—glaucoma	0.000204	0.000425	CcSEcCtD
Everolimus—Decreased appetite—Clonidine—glaucoma	0.000204	0.000425	CcSEcCtD
Everolimus—Infection—Betaxolol—glaucoma	0.000203	0.000423	CcSEcCtD
Everolimus—Gastrointestinal disorder—Clonidine—glaucoma	0.000202	0.000422	CcSEcCtD
Everolimus—Fatigue—Clonidine—glaucoma	0.000202	0.000421	CcSEcCtD
Everolimus—Dizziness—Brinzolamide—glaucoma	0.000202	0.000421	CcSEcCtD
Everolimus—Nausea—Acetazolamide—glaucoma	0.000201	0.00042	CcSEcCtD
Everolimus—Diarrhoea—Pilocarpine—glaucoma	0.000201	0.000419	CcSEcCtD
Everolimus—Shock—Betaxolol—glaucoma	0.000201	0.000418	CcSEcCtD
Everolimus—Constipation—Clonidine—glaucoma	0.000201	0.000418	CcSEcCtD
Everolimus—Pain—Clonidine—glaucoma	0.000201	0.000418	CcSEcCtD
Everolimus—Nervous system disorder—Betaxolol—glaucoma	0.0002	0.000417	CcSEcCtD
Everolimus—Dysgeusia—Timolol—glaucoma	0.0002	0.000417	CcSEcCtD
Everolimus—Thrombocytopenia—Betaxolol—glaucoma	0.0002	0.000416	CcSEcCtD
Everolimus—Tachycardia—Betaxolol—glaucoma	0.000199	0.000415	CcSEcCtD
Everolimus—Skin disorder—Betaxolol—glaucoma	0.000198	0.000413	CcSEcCtD
Everolimus—Vomiting—Dorzolamide—glaucoma	0.000198	0.000412	CcSEcCtD
Everolimus—Hyperhidrosis—Betaxolol—glaucoma	0.000197	0.000411	CcSEcCtD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—CDKN1B—glaucoma	0.000197	0.000981	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—CDKN1B—glaucoma	0.000197	0.000981	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—CDKN1B—glaucoma	0.000197	0.000981	CbGpPWpGaD
Everolimus—Rash—Dorzolamide—glaucoma	0.000196	0.000408	CcSEcCtD
Everolimus—Dermatitis—Dorzolamide—glaucoma	0.000196	0.000408	CcSEcCtD
Everolimus—Rash—Travoprost—glaucoma	0.000195	0.000406	CcSEcCtD
Everolimus—Dermatitis—Travoprost—glaucoma	0.000195	0.000406	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—CDKN1B—glaucoma	0.000195	0.000972	CbGpPWpGaD
Everolimus—Headache—Dorzolamide—glaucoma	0.000195	0.000406	CcSEcCtD
Everolimus—Anorexia—Betaxolol—glaucoma	0.000195	0.000405	CcSEcCtD
Everolimus—Vomiting—Brinzolamide—glaucoma	0.000194	0.000405	CcSEcCtD
Everolimus—Dizziness—Pilocarpine—glaucoma	0.000194	0.000405	CcSEcCtD
Everolimus—Headache—Travoprost—glaucoma	0.000194	0.000404	CcSEcCtD
Everolimus—Nausea—Brimonidine—glaucoma	0.000193	0.000403	CcSEcCtD
Everolimus—Feeling abnormal—Clonidine—glaucoma	0.000193	0.000403	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—CDKN1B—glaucoma	0.000193	0.000964	CbGpPWpGaD
Everolimus—Rash—Brinzolamide—glaucoma	0.000193	0.000401	CcSEcCtD
Everolimus—Vision blurred—Timolol—glaucoma	0.000193	0.000401	CcSEcCtD
Everolimus—Dermatitis—Brinzolamide—glaucoma	0.000192	0.000401	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—BAD—glaucoma	0.000192	0.00096	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—CDKN1B—glaucoma	0.000192	0.000959	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Clonidine—glaucoma	0.000192	0.000399	CcSEcCtD
Everolimus—Headache—Brinzolamide—glaucoma	0.000191	0.000399	CcSEcCtD
Everolimus—Hypotension—Betaxolol—glaucoma	0.000191	0.000397	CcSEcCtD
Everolimus—MTOR—Immune System—C1QB—glaucoma	0.000189	0.000944	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HDAC9—glaucoma	0.000188	0.000937	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TP53—glaucoma	0.000188	0.000936	CbGpPWpGaD
Everolimus—Angioedema—Timolol—glaucoma	0.000187	0.000389	CcSEcCtD
Everolimus—Vomiting—Pilocarpine—glaucoma	0.000187	0.000389	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Betaxolol—glaucoma	0.000186	0.000387	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—glaucoma	0.000186	0.000926	CbGpPWpGaD
Everolimus—Abdominal pain—Clonidine—glaucoma	0.000185	0.000386	CcSEcCtD
Everolimus—Body temperature increased—Clonidine—glaucoma	0.000185	0.000386	CcSEcCtD
Everolimus—Rash—Pilocarpine—glaucoma	0.000185	0.000386	CcSEcCtD
Everolimus—Dermatitis—Pilocarpine—glaucoma	0.000185	0.000385	CcSEcCtD
Everolimus—Insomnia—Betaxolol—glaucoma	0.000185	0.000385	CcSEcCtD
Everolimus—Nausea—Dorzolamide—glaucoma	0.000185	0.000385	CcSEcCtD
Everolimus—Headache—Pilocarpine—glaucoma	0.000184	0.000383	CcSEcCtD
Everolimus—Nausea—Travoprost—glaucoma	0.000184	0.000383	CcSEcCtD
Everolimus—Paraesthesia—Betaxolol—glaucoma	0.000183	0.000382	CcSEcCtD
Everolimus—Syncope—Timolol—glaucoma	0.000183	0.000382	CcSEcCtD
Everolimus—Dyspnoea—Betaxolol—glaucoma	0.000182	0.000379	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—OPN4—glaucoma	0.000182	0.000908	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—CDKN1B—glaucoma	0.000182	0.000908	CbGpPWpGaD
Everolimus—Nausea—Brinzolamide—glaucoma	0.000181	0.000378	CcSEcCtD
Everolimus—Palpitations—Timolol—glaucoma	0.000181	0.000376	CcSEcCtD
Everolimus—Dyspepsia—Betaxolol—glaucoma	0.00018	0.000374	CcSEcCtD
Everolimus—Loss of consciousness—Timolol—glaucoma	0.00018	0.000374	CcSEcCtD
Everolimus—Cough—Timolol—glaucoma	0.000178	0.000371	CcSEcCtD
Everolimus—Decreased appetite—Betaxolol—glaucoma	0.000177	0.00037	CcSEcCtD
Everolimus—Hypertension—Timolol—glaucoma	0.000176	0.000368	CcSEcCtD
Everolimus—Gastrointestinal disorder—Betaxolol—glaucoma	0.000176	0.000367	CcSEcCtD
Everolimus—Fatigue—Betaxolol—glaucoma	0.000176	0.000367	CcSEcCtD
Everolimus—Pain—Betaxolol—glaucoma	0.000175	0.000364	CcSEcCtD
Everolimus—Constipation—Betaxolol—glaucoma	0.000175	0.000364	CcSEcCtD
Everolimus—Nausea—Pilocarpine—glaucoma	0.000174	0.000363	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—CDKN1B—glaucoma	0.000174	0.000869	CbGpPWpGaD
Everolimus—Myalgia—Timolol—glaucoma	0.000174	0.000362	CcSEcCtD
Everolimus—Arthralgia—Timolol—glaucoma	0.000174	0.000362	CcSEcCtD
Everolimus—Chest pain—Timolol—glaucoma	0.000174	0.000362	CcSEcCtD
Everolimus—Anxiety—Timolol—glaucoma	0.000173	0.000361	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.000173	0.00036	CcSEcCtD
Everolimus—Hypersensitivity—Clonidine—glaucoma	0.000173	0.00036	CcSEcCtD
Everolimus—Discomfort—Timolol—glaucoma	0.000172	0.000358	CcSEcCtD
Everolimus—Dry mouth—Timolol—glaucoma	0.00017	0.000354	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—HEYL—glaucoma	0.000169	0.000845	CbGpPWpGaD
Everolimus—MTOR—Immune System—TXN—glaucoma	0.000169	0.000842	CbGpPWpGaD
Everolimus—Asthenia—Clonidine—glaucoma	0.000168	0.00035	CcSEcCtD
Everolimus—Feeling abnormal—Betaxolol—glaucoma	0.000168	0.00035	CcSEcCtD
Everolimus—Oedema—Timolol—glaucoma	0.000167	0.000347	CcSEcCtD
Everolimus—Pruritus—Clonidine—glaucoma	0.000166	0.000346	CcSEcCtD
Everolimus—Infection—Timolol—glaucoma	0.000166	0.000345	CcSEcCtD
Everolimus—Shock—Timolol—glaucoma	0.000164	0.000342	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—PTGFR—glaucoma	0.000164	0.000818	CbGpPWpGaD
Everolimus—Nervous system disorder—Timolol—glaucoma	0.000164	0.000341	CcSEcCtD
Everolimus—Skin disorder—Timolol—glaucoma	0.000162	0.000337	CcSEcCtD
Everolimus—Body temperature increased—Betaxolol—glaucoma	0.000161	0.000336	CcSEcCtD
Everolimus—Hyperhidrosis—Timolol—glaucoma	0.000161	0.000336	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—CDKN2A—glaucoma	0.000161	0.000804	CbGpPWpGaD
Everolimus—Diarrhoea—Clonidine—glaucoma	0.00016	0.000334	CcSEcCtD
Everolimus—Anorexia—Timolol—glaucoma	0.000159	0.000331	CcSEcCtD
Everolimus—CYP3A4—Biological oxidations—GSTT1—glaucoma	0.000157	0.000783	CbGpPWpGaD
Everolimus—Hypotension—Timolol—glaucoma	0.000156	0.000325	CcSEcCtD
Everolimus—Dizziness—Clonidine—glaucoma	0.000155	0.000323	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Timolol—glaucoma	0.000152	0.000317	CcSEcCtD
Everolimus—Insomnia—Timolol—glaucoma	0.000151	0.000314	CcSEcCtD
Everolimus—MTOR—Disease—HDAC9—glaucoma	0.000151	0.000753	CbGpPWpGaD
Everolimus—Hypersensitivity—Betaxolol—glaucoma	0.00015	0.000313	CcSEcCtD
Everolimus—Paraesthesia—Timolol—glaucoma	0.00015	0.000312	CcSEcCtD
Everolimus—Vomiting—Clonidine—glaucoma	0.000149	0.000311	CcSEcCtD
Everolimus—Dyspnoea—Timolol—glaucoma	0.000149	0.00031	CcSEcCtD
Everolimus—Somnolence—Timolol—glaucoma	0.000148	0.000309	CcSEcCtD
Everolimus—Rash—Clonidine—glaucoma	0.000148	0.000308	CcSEcCtD
Everolimus—Dermatitis—Clonidine—glaucoma	0.000148	0.000308	CcSEcCtD
Everolimus—Headache—Clonidine—glaucoma	0.000147	0.000306	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—SMO—glaucoma	0.000147	0.000733	CbGpPWpGaD
Everolimus—Dyspepsia—Timolol—glaucoma	0.000147	0.000306	CcSEcCtD
Everolimus—Asthenia—Betaxolol—glaucoma	0.000146	0.000305	CcSEcCtD
Everolimus—Decreased appetite—Timolol—glaucoma	0.000145	0.000302	CcSEcCtD
Everolimus—Pruritus—Betaxolol—glaucoma	0.000144	0.000301	CcSEcCtD
Everolimus—FKBP1A—Disease—CDKN2B—glaucoma	0.000144	0.00072	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Timolol—glaucoma	0.000144	0.0003	CcSEcCtD
Everolimus—Fatigue—Timolol—glaucoma	0.000144	0.0003	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—CDKN1B—glaucoma	0.000143	0.000712	CbGpPWpGaD
Everolimus—Pain—Timolol—glaucoma	0.000143	0.000297	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—glaucoma	0.00014	0.0007	CbGpPWpGaD
Everolimus—Diarrhoea—Betaxolol—glaucoma	0.00014	0.000291	CcSEcCtD
Everolimus—Nausea—Clonidine—glaucoma	0.000139	0.00029	CcSEcCtD
Everolimus—Feeling abnormal—Timolol—glaucoma	0.000137	0.000286	CcSEcCtD
Everolimus—Gastrointestinal pain—Timolol—glaucoma	0.000136	0.000284	CcSEcCtD
Everolimus—Dizziness—Betaxolol—glaucoma	0.000135	0.000281	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—NTRK2—glaucoma	0.000134	0.000671	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—CDKN1B—glaucoma	0.000134	0.000668	CbGpPWpGaD
Everolimus—Body temperature increased—Timolol—glaucoma	0.000132	0.000275	CcSEcCtD
Everolimus—Abdominal pain—Timolol—glaucoma	0.000132	0.000275	CcSEcCtD
Everolimus—Vomiting—Betaxolol—glaucoma	0.00013	0.00027	CcSEcCtD
Everolimus—Rash—Betaxolol—glaucoma	0.000129	0.000268	CcSEcCtD
Everolimus—Dermatitis—Betaxolol—glaucoma	0.000129	0.000268	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—RPTOR—glaucoma	0.000128	0.00064	CbGpPWpGaD
Everolimus—Headache—Betaxolol—glaucoma	0.000128	0.000266	CcSEcCtD
Everolimus—MTOR—Innate Immune System—C3—glaucoma	0.000126	0.000631	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—CYP1B1—glaucoma	0.000125	0.000624	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NCK2—glaucoma	0.000124	0.00062	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—CYP1B1—glaucoma	0.000123	0.000615	CbGpPWpGaD
Everolimus—Hypersensitivity—Timolol—glaucoma	0.000123	0.000256	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—C3—glaucoma	0.000121	0.000606	CbGpPWpGaD
Everolimus—Nausea—Betaxolol—glaucoma	0.000121	0.000253	CcSEcCtD
Everolimus—MTOR—Innate Immune System—BCL2L1—glaucoma	0.000121	0.000604	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MTHFR—glaucoma	0.000121	0.000603	CbGpPWpGaD
Everolimus—Asthenia—Timolol—glaucoma	0.00012	0.000249	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—VEGFA—glaucoma	0.000119	0.000593	CbGpPWpGaD
Everolimus—Pruritus—Timolol—glaucoma	0.000118	0.000246	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—NGFR—glaucoma	0.000115	0.000575	CbGpPWpGaD
Everolimus—Diarrhoea—Timolol—glaucoma	0.000114	0.000238	CcSEcCtD
Everolimus—FKBP1A—Disease—APOE—glaucoma	0.000112	0.000562	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CAV1—glaucoma	0.000111	0.000556	CbGpPWpGaD
Everolimus—Dizziness—Timolol—glaucoma	0.00011	0.00023	CcSEcCtD
Everolimus—CYP3A4—Metabolism—NARFL—glaucoma	0.00011	0.000549	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CA5A—glaucoma	0.00011	0.000549	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—BAD—glaucoma	0.00011	0.000547	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NTRK1—glaucoma	0.00011	0.000547	CbGpPWpGaD
Everolimus—Vomiting—Timolol—glaucoma	0.000106	0.000221	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—HDAC9—glaucoma	0.000106	0.000527	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—BAD—glaucoma	0.000105	0.000526	CbGpPWpGaD
Everolimus—Rash—Timolol—glaucoma	0.000105	0.000219	CcSEcCtD
Everolimus—Dermatitis—Timolol—glaucoma	0.000105	0.000219	CcSEcCtD
Everolimus—FKBP1A—Disease—BAD—glaucoma	0.000105	0.000523	CbGpPWpGaD
Everolimus—Headache—Timolol—glaucoma	0.000104	0.000218	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CDKN2B—glaucoma	0.000101	0.000504	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—GSTM1—glaucoma	9.99e-05	0.000499	CbGpPWpGaD
Everolimus—Nausea—Timolol—glaucoma	9.91e-05	0.000206	CcSEcCtD
Everolimus—CYP3A4—Metapathway biotransformation—GSTM1—glaucoma	9.85e-05	0.000492	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EDN1—glaucoma	9.69e-05	0.000484	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—TP53—glaucoma	8.97e-05	0.000448	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NGF—glaucoma	8.9e-05	0.000444	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—C3—glaucoma	8.46e-05	0.000422	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOS3—glaucoma	8.43e-05	0.000421	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL1A—glaucoma	8.38e-05	0.000418	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SMO—glaucoma	8.26e-05	0.000412	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN2B—glaucoma	8.11e-05	0.000405	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—APOE—glaucoma	7.88e-05	0.000393	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CAV1—glaucoma	7.8e-05	0.00039	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTGS2—glaucoma	7.71e-05	0.000385	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CDKN1B—glaucoma	7.63e-05	0.000381	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NTRK2—glaucoma	7.56e-05	0.000377	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FN1—glaucoma	7.43e-05	0.000371	CbGpPWpGaD
Everolimus—MTOR—Immune System—C3—glaucoma	7.36e-05	0.000367	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—BAD—glaucoma	7.34e-05	0.000366	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CDKN1B—glaucoma	7.33e-05	0.000366	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CDKN1B—glaucoma	7.3e-05	0.000364	CbGpPWpGaD
Everolimus—MTOR—Immune System—BCL2L1—glaucoma	7.05e-05	0.000352	CbGpPWpGaD
Everolimus—MTOR—Disease—MTHFR—glaucoma	6.8e-05	0.000339	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NGFR—glaucoma	6.48e-05	0.000324	CbGpPWpGaD
Everolimus—MTOR—Immune System—BAD—glaucoma	6.39e-05	0.000319	CbGpPWpGaD
Everolimus—MTOR—Disease—APOE—glaucoma	6.33e-05	0.000316	CbGpPWpGaD
Everolimus—MTOR—Disease—CAV1—glaucoma	6.27e-05	0.000313	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NTRK1—glaucoma	6.16e-05	0.000308	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOS3—glaucoma	5.9e-05	0.000295	CbGpPWpGaD
Everolimus—MTOR—Disease—BAD—glaucoma	5.9e-05	0.000294	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN2B—glaucoma	5.68e-05	0.000283	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EDN1—glaucoma	5.45e-05	0.000272	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CA1—glaucoma	5.37e-05	0.000268	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CTSA—glaucoma	5.2e-05	0.000259	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CDKN1B—glaucoma	5.11e-05	0.000255	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NGF—glaucoma	5.01e-05	0.00025	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CA2—glaucoma	4.91e-05	0.000245	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—C3—glaucoma	4.76e-05	0.000238	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS3—glaucoma	4.74e-05	0.000237	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP9—glaucoma	4.73e-05	0.000236	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDKN1B—glaucoma	4.45e-05	0.000222	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOE—glaucoma	4.43e-05	0.000221	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CAV1—glaucoma	4.39e-05	0.000219	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—glaucoma	4.33e-05	0.000216	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—glaucoma	4.25e-05	0.000212	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FN1—glaucoma	4.18e-05	0.000209	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—BAD—glaucoma	4.13e-05	0.000206	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN1B—glaucoma	4.11e-05	0.000205	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TXN—glaucoma	3.46e-05	0.000173	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOS3—glaucoma	3.32e-05	0.000166	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—glaucoma	3.21e-05	0.00016	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN1B—glaucoma	2.88e-05	0.000144	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTT1—glaucoma	2.68e-05	0.000134	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP9—glaucoma	2.66e-05	0.000133	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—glaucoma	2.39e-05	0.000119	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCA1—glaucoma	2.14e-05	0.000107	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP1B1—glaucoma	2.14e-05	0.000107	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—glaucoma	1.81e-05	9.02e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTM1—glaucoma	1.71e-05	8.53e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTHFR—glaucoma	1.51e-05	7.54e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOE—glaucoma	1.41e-05	7.02e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CAV1—glaucoma	1.39e-05	6.95e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NOS3—glaucoma	1.05e-05	5.26e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—glaucoma	9.63e-06	4.81e-05	CbGpPWpGaD
